Combined Epidermal Growth Factor Receptor and Beclin1 Autophagic Protein Expression Analysis Identifies Different Clinical Presentations, Responses to Chemo- and Radiotherapy, and Prognosis in Glioblastoma

Table 2

Clinical (Age = age at diagnosis, NPS = Neurological Performance Status, KPS = Karnofsky Performance Status), treatment (GTR = Macroscopic Gross Total Resection, B/STR = Biopsy or Sub-Total Tumor Resection, Dose RT = total dose for radiotherapy treatment, Sequential CHT = TMZ, sequentially administered after the RT-TMZ concomitant course), and biological (EGFR expression and Beclin-1 expression) prognostic factors (Kaplan-Meier method, Survival Analysis).

	pts	Progression Disease Free Survival	-value	Overall Survival	-value
		Median (months)		Median (months)
Age
>50	102	7	0.035	11	0.04
<50	15	17		18
NPS
class 1	20	10		15
class 2	41	4	0.0001	18	0.0001
class 3	34	3		11
class 4	22	1		5
KPS
100–80	91	9	0.001	15	0.0001
<70	26	2		5
Extent of Surgery
GTR	23	17	0.003	30	0.001
B/STR	94	5		10
Dose RT
<54 Gy	36	3	0.04	5	0.033
54–60 Gy	57	7		18
>60 Gy	24	10		16
Sequential CHT
yes	61	9	0.0001	15	0.0001
no	56	1		5
Synchronous Multifocality
yes	19	4	0.002	7	0.001
no	98	10		15
MGMT status
Methylated	38	20	0.002	22	0.003
Unmethylated	45	4		5
EGFR expression
Low	49	14	0.002	18	0.004
High	68	5		9
Beclin-1 expression
High	58	12	0.001	15	0.001
Low	59	4		5
EGFR and Beclin1 co-expression
L-EGFR; H-Beclin1	24	22	0.001	30	0.001
Others	93	8		11